RayKnowChina Research Map
Shortlist0

Harbin Medical University

哈尔滨医科大学

HarbinUniversity or health system

Hospitals that carry this university's name, added together, plus papers and trials that name only the university.

Research activity, not treatment quality. Not medical advice. How this works

Nasopharyngeal carcinoma

鼻咽癌
0.04%Leads under 1 in 100 of China's research papers on NPC

Led 1 of 2,375 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (23.4%).

Run this PubMed search

Open trials led
0
Research papers it led
1
Trials it led
1
Share of China's trials
0.2%
Share of the world's papers
0.03%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025
ThemesSide effects & quality of life

Hospitals counted here

  1. Second Affiliated Hospital of Harbin Medical University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Oesophageal squamous cell carcinoma

食管鳞状细胞癌
0.6%Leads under 1 in 100 of China's research papers on ESCC

Led 17 of 2,923 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.9%).

Run this PubMed search

Open trials led
0
Research papers it led
17
Trials it led
1
Share of China's trials
0.2%
Share of the world's papers
0.4%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 112025
ThemesImmunotherapyNeoadjuvant & combined treatmentImaging & AI

Hospitals counted here

  1. Harbin Medical University Cancer Hospital12
  2. Second Affiliated Hospital of Harbin Medical University Counted in the group total2
  3. First Affiliated Hospital of Harbin Medical University Counted in the group total1
  4. Fourth Affiliated Hospital of Harbin Medical University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Intratumoral and peritumoral heterogeneity based on CT to predict the pathological response after neoadjuvant chemoimmunotherapy in esophageal squamous cell carcinoma.2026International journal of surgery (London, England)Free full text
  2. Habitat-aware radiomics and adaptive 2.5D deep learning predict treatment response and long-term survival in ESCC patients undergoing neoadjuvant chemoimmunotherapy.2026European journal of nuclear medicine and molecular imaging
  3. Preoperative conversion therapy of camrelizumab combined with paclitaxel and nedaplatin for unresectable advanced esophageal squamous cell carcinoma: a phase 2 study.2025BMC medicineFree full text
  4. Dynamic radiological features predict pathological response after neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma.2024Journal of translational medicineFree full text
  5. Neoadjuvant camrelizumab combined with paclitaxel and nedaplatin for locally advanced esophageal squamous cell carcinoma: a single-arm phase 2 study (cohort study).2024International journal of surgery (London, England)Free full text
Trials on ClinicalTrials.gov6
  1. A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.Not yet recruitingNCT07623642Study sitePhase 2Start 2026-06
  2. SKB500 Combinations in Patients With Esophageal Squamous Cell CarcinomaRecruitingNCT07700667Study sitePhase 2Start 2026-08
  3. A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)RecruitingNCT06644781Study sitePhase 3Start 2025-03
  4. Low-Dose Radiotherapy With Retlirafusp Alfa and Chemotherapy as Neoadjuvant Therapy for Resectable Locally Advanced Esophageal Squamous Cell CarcinomaActive, not recruitingNCT07682376Lead sponsorPhase 2Start 2026-06
  5. A Study of Simmitinib Plus Irinotecan in Advanced Esophageal Squamous Cell CarcinomaStatus unknownNCT06512428Study sitePhase 2Start 2024-03
  6. A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell CarcinomaCompletedNCT06010303Study sitePhase 2Start 2023-11

PubMed searchClinicalTrials.gov

Hepatocellular carcinoma

肝细胞癌
1.1%Leads about 1 in 89 of China's research papers on HCC

Led 165 of 14,765 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (5.5%).

Run this PubMed search

Open trials led
1
Research papers it led
165
Trials it led
1
Share of China's trials
0.07%
Share of the world's papers
0.6%
Papers led per year
2021: 0020212022: 1120222023: 2220232024: 0020242025: 112025
ThemesRecurrence & prognosisImaging, AI & early detectionImmunotherapy & targeted drugs

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Harbin Medical University Cancer Hospital57
  2. Second Affiliated Hospital of Harbin Medical University49
  3. First Affiliated Hospital of Harbin Medical University31
  4. Fourth Affiliated Hospital of Harbin Medical University Counted in the group total8
  5. Fourth Hospital of Harbin Medical University6
  6. Affiliated Tumor Hospital of Harbin Medical University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. An offline to online cognitive behavioral stress management caring program effectively improves psychological pressure, spiritual well-being, and quality of life in postoperative hepatocellular carcinoma patients.2023Clinics and research in hepatology and gastroenterologyRCT
  2. Comparison of CalliSpheres® microspheres drug-eluting beads and conventional transarterial chemoembolization in hepatocellular carcinoma patients: a randomized controlled trial.2023Radiology and oncologyRCTFree full text
  3. A Ferroptosis-Related LncRNA Signature Associated with Prognosis, Tumor Immune Environment, and Genome Instability in Hepatocellular Carcinoma.2022Computational and mathematical methods in medicineRCTFree full text
  4. Spatiotemporal dynamics of T cells in peripheral blood and tumor underlying differential responses to neoadjuvant PD-1 blockade in hepatocellular carcinoma.2025Journal for immunotherapy of cancerFree full text
  5. An etiology-stratified single-cell atlas identifies FABP4 as a prognostic marker for MASLD-related HCC.2026Journal of hepatology
Trials on ClinicalTrials.gov6
  1. A Study of Cadonilimab Combined With AK112 as Second-line Therapy in Patients With Advanced Hepatocellular CarcinomaNot yet recruitingNCT06196775Lead sponsorPhase 2Start 2024-01
  2. Evaluate the Safety and Efficacy of Combination Therapy With SYS6090 Injection for Hepatocellular CarcinomaNot yet recruitingNCT07761286Study sitePhase 1/Phase 2Start 2026-09
  3. First in Human Study of SIM0610 in Solid TumorsRecruitingNCT07348211Study sitePhase 1Start 2026-01
  4. A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCCRecruitingNCT07547553Study sitePhase 1/Phase 2Start 2026-05
  5. The Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma A Multi-center, Retrospective Clinical StudyNot yet recruitingNCT07724951Study siteStart 2026-07
  6. JS207 Plus JS007 Versus Toripalimab Plus Bevacizumab as First-Line Treatment for Advanced Liver CancerNot yet recruitingNCT07823348Study sitePhase 3Start 2026-10

PubMed searchClinicalTrials.gov

Stomach cancer

胃癌
1.3%Leads about 1 in 78 of China's research papers on Stomach cancer

Led 125 of 9,782 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (3.9%).

Run this PubMed search

Open trials led
2
Research papers it led
125
Trials it led
6
Share of China's trials
0.4%
Share of the world's papers
0.6%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 332025
ThemesImaging & AIPeritoneal spread & advanced diseaseSurgery

Hospitals counted here

  1. Harbin Medical University Cancer Hospital65
  2. Second Affiliated Hospital of Harbin Medical University35
  3. Fourth Affiliated Hospital of Harbin Medical University11
  4. First Affiliated Hospital of Harbin Medical University Counted in the group total3
  5. Cancer Hospital, Harbin Medical University Counted in the group total2
  6. Third Affiliated Hospital of Harbin Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Effects of enhanced recovery after surgery nursing combined with early enteral nutrition on Gastrointestinal function recovery after radical gastrectomy.2025Langenbeck's archives of surgeryRCTFree full text
  2. Effect of sodium-reduced potassium-enriched salt substitutes on stomach cancer: the Salt Substitute and Stroke Study (SSaSS).2025BMC medicineRCTFree full text
  3. Integrating psychological and dietary care for patients with advanced gastric cancer undergoing chemotherapy: a randomized controlled trial.2025Supportive care in cancer : official journal of the Multinational Association of Supportive Care in CancerRCT
  4. Reminiscence therapy exhibits alleviation of anxiety and improvement of life quality in postoperative gastric cancer patients: A randomized, controlled study.2021MedicineRCTFree full text
  5. Ocular Safety Evaluation of Bemarituzumab in FGFR2b-Overexpressing Gastroesophageal Adenocarcinoma: A 42-Week Follow-Up Study.2026Ocular immunology and inflammation
Trials on ClinicalTrials.gov6
  1. Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric CancerRecruitingNCT07552402Lead sponsorN/AStart 2026-06
  2. AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ CancerRecruitingNCT06196697Lead sponsorPhase 2Start 2024-04
  3. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT07385703Study sitePhase 3Start 2026-04
  4. Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction CancerRecruitingNCT06731478Study sitePhase 3Start 2025-02
  5. Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction AdenocarcinomaRecruitingNCT07102901Study sitePhase 2Start 2025-09
  6. A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric CancerRecruitingNCT06901531Study sitePhase 3Start 2025-05

PubMed searchClinicalTrials.gov

Retinoblastoma

视网膜母细胞瘤
1.0%Leads about 1 in 100 of China's research papers on Retinoblastoma New since 2021

Led 3 of 301 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.0%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 2220212022: 1120222023: 0020232024: 0020242025: 002025

Hospitals counted here

  1. Fourth Affiliated Hospital of Harbin Medical University2
  2. First Affiliated Hospital of Harbin Medical University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Osteosarcoma

骨肉瘤
1.6%Leads about 1 in 65 of China's research papers on Osteosarcoma

Led 35 of 2,257 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
35
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.7%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 332025

Over half of these papers are lab or animal studies.

PubMed searchClinicalTrials.gov

Gastrointestinal stromal tumour

胃肠道间质瘤
0.6%Leads under 1 in 100 of China's research papers on Gastrointestinal stromal tumour

Led 3 of 523 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.3%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 112025

Hospitals counted here

  1. Harbin Medical University Cancer Hospital1
  2. Second Affiliated Hospital of Harbin Medical University1
  3. Fourth Affiliated Hospital of Harbin Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Neuroblastoma

神经母细胞瘤
0.6%Leads under 1 in 100 of China's research papers on Neuroblastoma

Led 7 of 1,132 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.8%).

Run this PubMed search

Open trials led
0
Research papers it led
7
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 4420242025: 002025

Over half of these papers are lab or animal studies.

PubMed searchClinicalTrials.gov

Multiple myeloma

多发性骨髓瘤
1.0%Leads about 1 in 99 of China's research papers on Myeloma

Led 17 of 1,676 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.8%).

Run this PubMed search

Open trials led
0
Research papers it led
17
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 0020242025: 112025
ThemesDiagnosis, MRD & riskRelapse & resistanceDrug combinations

Hospitals counted here

  1. Harbin Medical University Cancer Hospital6
  2. Second Affiliated Hospital of Harbin Medical University6
  3. First Affiliated Hospital of Harbin Medical University4
  4. Fourth Hospital of Harbin Medical University1
  5. Fourth Affiliated Hospital of Harbin Medical University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Study on autonomic neuropathy of the digestive system caused by bortezomib in the treatment of multiple myeloma.2023Hematology (Amsterdam, Netherlands)
  2. Dynamic monitoring of serum ferritin as an adverse prognostic biomarker in patients with multiple myeloma.2021Biomarkers in medicine
  3. Adhesion of Immunoglobulins to Band3 Promotes Increased Erythrocyte Sedimentation Rate in Multiple Myeloma.2026Cell proliferationFree full text
  4. Using RNA-seq for detecting MRD in multiple myeloma: high sensitivity and prognostic value.2026Cancer gene therapy
  5. HNRNPA2B1 Promotes the Progression of Multiple Myeloma via Endoplasmic Reticulum Stress and Autophagy Mediated by CK2 Kinase.2025Journal of proteome research
Trials on ClinicalTrials.gov6
  1. Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07569757Study sitePhase 3Start 2026-06
  2. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple MyelomaRecruitingNCT07477587Study sitePhase 1Start 2026-05
  3. Risk Stratification and MRD-driven Maintenance for MM After ASCTRecruitingNCT06697483Study siteN/AStart 2024-12
  4. A Study of YKST02 in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT06574568Study sitePhase 1Start 2024-06
  5. A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple MyelomaRecruitingNCT05552222Study sitePhase 3Start 2022-10
  6. A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT05572515Study sitePhase 3Start 2023-03

PubMed searchClinicalTrials.gov

B-cell acute lymphoblastic leukaemia (B-ALL)

B 细胞急性淋巴细胞白血病
1.3%Leads about 1 in 75 of China's research papers on B-ALL ▼ from 2.0%

Led 3 of 225 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.9%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 222025
ThemesAntibody & targeted drugsPhiladelphia chromosome & geneticsCAR-T & cell therapy

Hospitals counted here

  1. First Affiliated Hospital of Harbin Medical University2
  2. Second Affiliated Hospital of Harbin Medical University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Haemophilia A

血友病 A
0.7%Leads under 1 in 100 of China's research papers on Haemophilia A ▼ from 2.0%

Led 2 of 272 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (15.8%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.07%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 112025

Hospitals counted here

  1. Fourth Affiliated Hospital of Harbin Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Neuromyelitis optica spectrum disorder (NMOSD)

视神经脊髓炎谱系疾病
0.4%Leads under 1 in 100 of China's research papers on NMOSD New since 2021

Led 2 of 485 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.5%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 222025
ThemesAntibodies & diagnosis

Hospitals counted here

  1. Second Affiliated Hospital of Harbin Medical University1
  2. First Affiliated Hospital of Harbin Medical University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Myasthenia gravis

重症肌无力
2.4%Leads about 1 in 42 of China's research papers on Myasthenia gravis ▼ from 4.6%

Led 12 of 499 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.6%).

Run this PubMed search

Open trials led
0
Research papers it led
12
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.5%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 3320242025: 112025
ThemesAntibodies & diagnosisEye-only (ocular) myastheniaStandard immunotherapy

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Second Affiliated Hospital of Harbin Medical University8

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Moyamoya disease

烟雾病
0.6%Leads under 1 in 100 of China's research papers on Moyamoya New since 2021

Led 2 of 356 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (19.9%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 002025
ThemesGeneticsRevascularisation surgeryImaging & blood flow

Hospitals counted here

  1. First Affiliated Hospital of Harbin Medical University2
  2. Fourth Affiliated Hospital of Harbin Medical University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Idiopathic pulmonary fibrosis

特发性肺纤维化
1.7%Leads about 1 in 58 of China's research papers on Idiopathic pulmonary fibrosis ▼ from 2.4%

Led 17 of 989 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
17
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 332025

Hospitals counted here

  1. Second Affiliated Hospital of Harbin Medical University11
  2. First Affiliated Hospital of Harbin Medical University2
  3. Fourth Affiliated Hospital of Harbin Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症
1.7%Leads about 1 in 60 of China's research papers on Amyotrophic lateral sclerosis ▼ from 2.3%

Led 13 of 779 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.3%).

Run this PubMed search

Open trials led
0
Research papers it led
13
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 552025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. First Affiliated Hospital of Harbin Medical University11
  2. Affiliated Hospital of Harbin Medical University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Behçet disease

白塞病
0.8%Leads under 1 in 100 of China's research papers on Behçet disease

Led 2 of 245 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (22.9%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

Hospitals counted here

  1. Second Affiliated Hospital of Harbin Medical University1
  2. First Affiliated Hospital of Harbin Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

IgA nephropathy

IgA 肾病
0.8%Leads under 1 in 100 of China's research papers on IgA nephropathy ▼ from 2.4%

Led 6 of 736 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.4%).

Run this PubMed search

Open trials led
0
Research papers it led
6
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 2220212022: 0020222023: 0020232024: 1120242025: 222025

Hospitals counted here

  1. Second Affiliated Hospital of Harbin Medical University3
  2. First Affiliated Hospital of Harbin Medical University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Gaucher disease

戈谢病
6.7%Leads about 1 in 15 of China's research papers on Gaucher disease New since 2021

Led 2 of 30 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.7%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 2220212022: 0020222023: 0020232024: 0020242025: 002025

PubMed searchClinicalTrials.gov

Hirschsprung disease

先天性巨结肠
1.2%Leads about 1 in 81 of China's research papers on Hirschsprung disease New since 2021

Led 2 of 161 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (13.0%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 002025

Hospitals counted here

  1. Affiliated Hospital of Harbin Medical University1
  2. First Affiliated Hospital of Harbin Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov